SENSEI BIOTHERAPEUTICS INC (SNSE)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$13.85+6.54%
Close 2026-06-15 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put SNSE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — Negative cash from operations near or below $10.7M in 2026-Q1: Comparison needs review.
View ThesisThis stock is volatile — it swings about 3% on a typical day and fell roughly 69% in its worst 12-month stretch.
View RiskSNSE’s case depends on recovery, but the desk has no earnings history or catalysts. The company was unprofitable over the past year, with weak recent financial performance. No earnings release is recorded, so no recent beat or miss is verified. No valuation multiple or peer comparison is available to show what expectations price in. Our model puts the next-quarter miss probability near 74%. The cash-flow pillar is under pressure, though its comparison needs review. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-06-15. SNSE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering SNSE (as of Jun 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SNSE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SNSE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SNSE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-06-15. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.